MannKind at neutral by Merrill

Merrill Lynch analyst Hari Sambasivam rated MannKind Corp. at neutral ahead of the company's earnings call on Nov. 2. The analyst estimates total expenses of $58.0 million, including research and development spending of $47.5 million, and estimated a pro forma net loss of $58.6 million, or $1.18 per share. Sambasivam will look for updates on MannKind's plans to manage the cash burn of approximately $50 million per quarter during the call. Shares of the Valencia, Calif.-based biopharmaceutical company were up 8 cents, or 0.41%, at $19.67. (Nasdaq: MNKD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.